Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Fine-Tuning Strategic Assessment.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Roots Analysis

MARCH 2, 2022

Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Pipeline Overview of Oral Peptide and Protein-based Therapeutics.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

The Pharma Data

JANUARY 7, 2021

Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs). The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

Delveinsight

FEBRUARY 16, 2021

Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Takeda wins big in cytomegalovirus infection market.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Roots Analysis

OCTOBER 2, 2023

Additionally, it increases the bioavailability and solubility of the attached molecule. It is worth noting that in case of oncological disorders, nanoparticles are being developed to increase the permeability and stability of chemotherapeutics agents through the delivery of both diagnostic and therapeutic agents.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Marketing 40

Pharmaceutical Technology

JANUARY 25, 2023

Development of PROTACs (PROteolysis TArgeting Chimeras) has advanced fairly rapidly as excitement grows over their potential to selectively degrade proteins that are involved in various diseases, including cancer. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.

Protein 130

Protein Bioavailability Development Scientist 130

Roots Analysis

MARCH 1, 2022

Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Bioavailability 52

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Roots Analysis

MARCH 13, 2022

Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Biopharmaceutical excipients can range from simple inert entities to complex compounds.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

SEPTEMBER 1, 2023

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

Pharmaceutical Technology

AUGUST 22, 2022

They also offer enhanced bioavailability, exact dosing and an extended shelf life. Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets. Compared to traditional hard capsules or granules, they are easier to swallow and more attractive in appearance. The best formulation for the job.

Compliance 130

Compliance Bioavailability Containment Branding 130

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

XTalks

FEBRUARY 25, 2022

After five years of research and development, the brand found a way to transform saved grain from brewing into nutrient-rich, barley-based proteins and fibers that have a variety of applications in the food and beverage industry. billion by 2027 at a compound annual growth rate (CAGR) of two percent, according to Research and Markets.

Production 98

Production Protein Branding Bioavailability 98

pharmaphorum

AUGUST 19, 2022

If all goes well, the aim is to bring resiniferatoxin to market in 2025. Among these still in development, Glenmark’s orally active GRC17536 cleared a phase 2a study in diabetic neuropathy but has bioavailability issues that have held up a phase 3 programme.

Drugs 52

Drugs Bioavailability Trials Clinical Development 52

pharmaphorum

MAY 5, 2021

. “The public believes that pharmaceutical companies should be fairly compensated for developing vaccines, but should be prevented from holding a monopoly on the jabs,” says the Alliance, adding that people “don’t want big pharma to hold monopolies on vaccines that were developed largely with public money.”

Vaccination 105

Vaccination Vaccine Sales Bioavailability 105

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

Roots Analysis

JANUARY 28, 2024

By analyzing this data, healthcare organizations can identify patterns and trends, predict patient outcomes, and develop personalized treatment plans. Conclusion Owing to the increasing popularity of big data in healthcare domain, there is a huge impact of big data in healthcare market size.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

XTalks

FEBRUARY 3, 2023

Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Finnish time. About Nanoform.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

Delveinsight

JANUARY 7, 2021

Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The startup recently raised USD 87 million to propel itself in a competitive market. Under the terms of the deal, Ribometrix and Genentech, a member of the Roche Group, will collaborate on discovering and preclinical development of programs.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

MARCH 8, 2021

“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Camargo

SEPTEMBER 30, 2021

The drug development process is a long journey, beginning with drug discovery, moving through nonclinical and clinical studies, and ultimately culminating in regulatory approval. This blog post offers advice for avoiding major pitfalls during the drug development process. Overview of a Drug Development Program. Take a look.

Development 201

Development Research Manufacturing In-Vivo 201

Pharmaceutical Technology

AUGUST 3, 2022

The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development. Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market.

Development 130

Development Production Manufacturing Bioavailability 130

The Pharma Data

JANUARY 3, 2021

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. Finnish time.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. It also showed that Nefecon was generally well-tolerated.

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.

Bioavailability 130

Bioavailability In-Vivo In-Vitro Licensing 130

Delveinsight

SEPTEMBER 8, 2021

BENLYSTA (Belimumab) is developed by the pharma giant GlaxoSmithKline (GSK) and it is the first and only FDA-approved therapy for both lupus and lupus nephritis. As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Anifrolumab (MEDI-546).

Marketing 52

Marketing Sales FDA Approval Antibody 52

Drug Discovery World

DECEMBER 7, 2022

By Dr Natalia Dadivanyan , Segment Marketing Manager, Malvern Panalytical . Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. Small molecules can face big challenges .

Bioavailability 52

Bioavailability Manufacturing Production Development 52

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

The Pharma Data

DECEMBER 3, 2020

Achieving the primary endpoint of the SOLSTICE trial is an exciting new development in the search for a treatment for transplant recipients with refractory/resistant CMV infection. No new safety signals were identified and maribavir was associated with lower incidence of neutropenia compared to IAT. About Maribavir.

Drugs 52

Drugs Medicine Trials Containment 52

The Pharma Data

DECEMBER 1, 2020

NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the open-label Phase 2 COMET-TRD trial of AXS-05 in patients with treatment resistant depression (TRD). AXS-07 is being developed for the acute treatment of migraine.

Trials 52

Trials Clinical Trials Clinical Trials Production 52

Pharmaceutical Technology

NOVEMBER 24, 2022

Few contract development and manufacturing organizations (CDMOs) are able to provide radiolabeling services as part of a fully integrated pharmaceutical development program. How does your unique Synthesis-to-Clinic® offering streamline the drug development process? How are human ADME studies designed?

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

The Pharma Data

MARCH 11, 2021

Additionally, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, will present preclinical characterization data for an oral selective estrogen receptor degrader (SERD), BCL2 inhibitor, next-generation KRAS-G12C inhibitor, and next-generation RET inhibitor. Abstract Number: 1236. About Sintilimab.

Research 52

Research Clinical Trials Clinical Trials Trials 52

The Pharma Data

DECEMBER 3, 2020

(TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. ” said Yufang Hu , Ph.D.,

Licensing 52

Licensing Licensing Bioavailability DNA 52

Drug Discovery World

AUGUST 9, 2023

The CCDC team is made up of scientists from the University of Leeds, Tianjin University, and AbbVie. The development of Ritonavir Ritonavir is a drug for the treatment of Acquired Immuno-Deficiency Syndrome (AIDS) marketed in 1996.

Research 52

Research Bioavailability Scientist Drugs 52